In appropriate patients, AIS treatment involves tissue plasminogen activator (tPA)/tenecteplase (TNK) fibrinolysis (within 4.5 h from onset) or thrombectomy. The gene discussed is PLAT; the disease is androgen insensitivity syndrome.